Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.77
- Piotroski Score 4.00
- Grade Neutral
- Symbol (RCUS)
- Company Arcus Biosciences, Inc.
- Price $15.29
- Changes Percentage (-1.74%)
- Change -$0.27
- Day Low $15.03
- Day High $15.50
- Year High $20.31
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/06/2024
- Fiscal Year End N/A
- Average Stock Price Target $32.00
- High Stock Price Target $46.00
- Low Stock Price Target $20.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.11
- Trailing P/E Ratio -4.98
- Forward P/E Ratio -4.98
- P/E Growth -4.98
- Net Income $-307,000,000
Income Statement
Quarterly
Annual
Latest News of RCUS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Demarcus Robinson's one-handed TD grab gives Rams OT win over Seahawks: Key takeaways
Matthew Stafford's 39-yard TD pass to Demarcus Robinson sealed the Rams' 26-20 win over the Seahawks in a crucial NFC West clash. The Rams rallied from a 10-point halftime deficit, with the defense ma...
By The New York Times | 1 day ago -
Marcus Harris II scores go-ahead touchdown in 4th quarter and Alabama State tops Alcorn State 21-17
Alabama State defeated Alcorn State 21-17 with Marcus Harris II's touchdown run in the fourth quarter. Despite fewer yards, Alabama State capitalized on turnovers for the victory in a close game....
By AP NEWS | 2 days ago -
Marcus Corp (MCS) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Moves
Greg Marcus of Marcus Corp discusses how theaters benefit during recessions, citing affordable entertainment. The company is open to M&A opportunities but notes potential sellers waiting for stability...
By Yahoo! Finance | 4 days ago
